


Figure 2. Influenza Positive Tests and Percent Positive, Denton County Hospitals and Providers



* Percent positive tests only includes positive tests from providers reporting number of tests performed weekly

Figure 3. Influenza Positive Tests Reported to CDC by U.S. Public Health Laboratories, National Summary, 2015-16 Season




Figure 4. Influenza Positive Tests Reported to CDC by U.S. Clinical Laboratories, National Summary, 2015-16 Season




Figure 5. U.S. Virologic Surveillance, Week 49 and Cumulative Data since October 4, 2015

	Week 49	Data Cumulative since October 4, 2015 (Week 40)
No. of specimens tested	12,525	133,503
No. of positive specimens (%)	208 (1.7%)	1,765 (1.3%)
<i>Positive specimens by type</i>		
Influenza A	117 (56.3%)	1,061 (60.1%)
Influenza B	91 (43.8%)	704 (39.9%)

Figure 8. Antigenic Characterization of Influenza Isolates

2009 Influenza A (H1N1)	18 of 18 (100%) – A/California/7/2009-like
Influenza A (H3N2)	100 of 100 (100%) – A/Switzerland/9715293/2013 similar
Influenza B (Yamagata Lineage)	9 of 9 (100%) – B/Phuket/3073/2013-like
Influenza B (Victoria Lineage)	7 of 7 (100%) – B/Brisbane/60/2008-like*

www.cdc.gov/flu/weekly

2015-16 Influenza Vaccine Composition, Northern Hemisphere:

- A/California/7/2009 (H1N1)-like virus
- A/Switzerland/9715293/2013 (H3N2)-similar virus
- B/Phuket/3073/2013-like virus
- B/Brisbane/60/2008-like virus*

* 2015-2016 Northern Hemisphere quadrivalent influenza vaccine influenza B component

Figure 9. Neuraminidase Inhibitor Resistance Testing Results on Samples Collected Since October 1, 2015

	Oseltamivir		Zanamivir		Peramivir	
	Virus Samples tested (n)	Resistant Viruses, Number (%)	Virus Samples tested (n)	Resistant Viruses, Number (%)	Virus Samples tested (n)	Resistant Viruses, Number (%)
Influenza A (H1N1)pdm09	25	1 (4.0)	25	0 (0.0)	25	1 (4.0)
Influenza A (H3N2)	117	0 (0.0)	117	0 (0.0)	117	0 (0.0)
Influenza B	21	0 (0.0)	21	0 (0.0)	21	0 (0.0)

** www.cdc.gov/flu/weekly
Antiviral treatment with oseltamivir, zanamivir, or peramivir is recommended as early as possible for patients with confirmed or suspected influenza who have severe, complicated, or progressive illness; who require hospitalization; or who are at high risk for serious influenza-related complications.

Figure 10. Pneumonia and Influenza Mortality for 122 U.S. Cities: Week ending December 12, 2015






Figure 11. Weekly Influenza Activity Estimates Reported by State and Territorial Epidemiologists* Week Ending December 12, 2015 – Week 49



*This graph indicates geographic spread and does not measure the severity of influenza activity.

Figure 12. Percentage of Respiratory Specimens that Tested Positive for Influenza: WHO, as of December 10, 2015*



*Based on data up to November 29, 2015